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Abstract
The D-arabinan-containing polymers arabinogalactan (AG) and lipoarabinomannan (LAM) are essential components of the
unique cell envelope of the pathogen Mycobacterium tuberculosis. Biosynthesis of AG and LAM involves a series of
membrane-embedded arabinofuranosyl (Araf) transferases whose structures are largely uncharacterised, despite the fact
that several of them are pharmacological targets of ethambutol, a frontline drug in tuberculosis therapy. Herein, we present
the crystal structure of the C-terminal hydrophilic domain of the ethambutol-sensitive Araf transferase M. tuberculosis EmbC,
which is essential for LAM synthesis. The structure of the C-terminal domain of EmbC (EmbC
CT) encompasses two sub-
domains of different folds, of which subdomain II shows distinct similarity to lectin-like carbohydrate-binding modules
(CBM). Co-crystallisation with a cell wall-derived di-arabinoside acceptor analogue and structural comparison with ligand-
bound CBMs suggest that EmbC
CT contains two separate carbohydrate binding sites, associated with subdomains I and II,
respectively. Single-residue substitution of conserved tryptophan residues (Trp868, Trp985) at these respective sites
inhibited EmbC-catalysed extension of LAM. The same substitutions differentially abrogated binding of di- and penta-
arabinofuranoside acceptor analogues to EmbC
CT, linking the loss of activity to compromised acceptor substrate binding,
indicating the presence of two separate carbohydrate binding sites, and demonstrating that subdomain II indeed functions
as a carbohydrate-binding module. This work provides the first step towards unravelling the structure and function of a GT-
C-type glycosyltransferase that is essential in M. tuberculosis.
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Introduction
Tuberculosis (TB) affects large parts of the world’s population,
particularly in developing countries [1]. The antibiotics isoniazid
(INH) and ethambutol (EMB) [2] have been used for decades as
frontline drugs to treat Mycobacterium tuberculosis infections, the
causative agent of TB, but the rise of multi-drug resistant (MDR)
and extensively drug resistant (XDR) strains poses a serious threat
to present treatment options [3]. Both, INH and EMB inhibit the
synthesis of essential components of the mycobacterial cell wall.
This unique and highly impermeable barrier surrounds a single
phospholipid bilayer membrane and is composed of an outer
segment of solvent-extractable lipids, glycans and proteins, and a
covalently linked inner segment, known as the mycolyl-arabino-
galactan-peptidoglycan (mAGP) core [4]. Perturbations to the
mAGP core tend to undermine viability of M. tuberculosis, a major
reason why mAGP biosynthesis constitutes an attractive target for
drug design efforts. The mycobacterial cell wall also encompasses
various membrane-anchored lipoglycans, a group that includes
lipoarabinomannan (LAM), which plays a key role in modulating
the host immune response [5]. The arabinogalactan (AG) segment
of the mAGP core and LAM both contain D-arabinan polymer,
composed of a(1R5), a(1R3) and b(1R2)-linked arabinofuranosyl
(Araf) residues that are assembled in distinct structural motifs
(Fig. 1A) [4,5].
In recent years, substantial progress has been made in defining
the enzymatic processes resulting in the complete synthesis of AG
and LAM [6–14]. Probing susceptibility to EMB, initial studies
established that this inhibitor acted on a set of closely related
arabinofuranosyl (Araf) transferases, EmbC (Rv3793), EmbA
(Rv3794) and EmbB (Rv3795) [6,7], collectively referred to as
the Emb enzymes. These three proteins belong to the glycosyl-
transferase superfamily C (GT-C), which encompasses a diverse set
of membrane-embedded glycosyltransferases that utilise lipid-
linked as opposed to nucleotide-linked sugars as donor substrates
(Fig. 1A) [15]. The Emb enzymes of M. tuberculosis display a
common architecture of 13 transmembrane helices in conjunction
with a hydrophilic C-terminal domain [10,14] (Fig. 1B), and share
the same polyprenyl donor-substrate, b-D-arabinofuranosyl-1-
monophosphoryldecaprenol (DPA) [16,17].
Owing to their hydrophobic nature, generating recombinant
Emb proteins in soluble form has proved difficult, hampering in vitro
characterisation. As a result, the function of the Emb enzymes has
been delineated by genetics, phenotypic analysis of the cell envelope
PLoS Pathogens | www.plospathogens.org 1 February 2011 | Volume 7 | Issue 2 | e1001299and cell-free assays. Single gene deletions of embC, embB in M.
tuberculosis are lethal [18,19], but corresponding knock-outs in
Mycobacterium smegmatis or Corynebacterium glutamicum yield viable,
albeit slow growing mutants, whose cell wall defects can be analysed
[8,9]. Following attachment of the initial Araf residue to the linear
galactan polymer [Galf-b(1R5)Galf-b(1R6)]n, catalysed by the
Araf-transferase AftA [12], EmbA and EmbB extend the arabinan
chain in AG synthesis, transferring Araf residues from DPA to
polysaccharide acceptors [8,9]. Highly similar in amino acid
sequence (,40% identity, see also Supporting Fig. S1), EmbA,B
and EmbC have differential roles: the DembA,B deletions inhibit AG
synthesis, but leave LAM synthesis intact, whereas the DembC
deletion only affects LAM synthesis. Chimaeric forms of the Emb
enzymes, where the hydrophilic C-terminal domain of EmbC was
swapped for that of EmbB led to a hybrid-LAM, bearing an AG-
specific, branched Araf6 group instead of the characteristic LAM-
specific linear Araf4 [9]. These data indicated that the hydrophilic
C-terminal domain makes a critical contribution to determining the
structure of the resulting AG or LAM segments.
To date, the Emb enzymes have remained poorly characterised
in structural terms, despite their central significance as targets of
the TB antibiotic EMB and their link to drug resistance [20].
Herein, we present the crystal structure of the C-terminal
hydrophilic domain of M. tuberculosis EmbC (residues 719–1094,
henceforth EmbC
CT), as a first step towards the elucidation of the
3D structure of the full-length enzyme.
Results
Structure determination and domain architecture
EmbC
CT crystallised in space group P6522 over a diverse range
of reservoir conditions, with one molecule in the crystallographic
asymmetric unit. Crystals were generated with or without an Araf
acceptor analogue (see below) present in the crystallisation droplet.
The experimental density, phased by multi-wavelength anomalous
dispersion (2.7 A ˚, Table 1), was of very good quality (Fig. S2A),
defining the structure for residues 735–1067, except for two
disordered loops (795–824 and 1016–1037, Fig. 2A). EmbC
CT is
composed of two distinct subdomains, separated by a deep crevice
marked by the disordered loops (residues 795–824 and 1016–
1037). Subdomain I, which encompasses residues 746–760 and
967–1067, displays a mixed a/b structure, with a 5-stranded b-
sheet forming a semi-barrel (Fig. 2A). The long H6-S13 loop,
which forms a minor crystal packing interface, protrudes from the
core of subdomain I with a helical half-turn at its tip (Fig. 2A).
Subdomain II (residues 761–966) forms an anti-parallel b-
sandwich structure, of which the ‘outer’ sheet (S2, S4, S10, S6,
S7) faces solvent while the ‘inner’ sheet (S3, S11, S5, S9, S8) packs
against the core of the domain (Fig. 2A). The b-sandwich of
subdomain II assumes a jellyroll fold (Fig. 2B), a fold typical for
polysaccharide binding units in plant lectins and carbohydrate
active enzymes [21]. Although not part of the formal jellyroll
description, strands S2 and S8 extend the ‘outer’ and ‘inner’ sheet,
respectively, while helix H4 forms a boundary to the ‘outer’ sheet.
A high-density peak (14s, anomalous density difference map,
Fig. 3A) is embedded between loops S3–S4 and S10–S11. Quasi-
octahedral coordination geometry and the distribution of peak-
ligand distances from 2.40 to 2.63 A ˚ (Fig. 3A) suggest a bound
Ca
2+ ion [22]. The metal ion appears shielded from solvent,
although including 10 mM EDTA in the cryoprotectant buffer
significantly diminished the height of the density peak (Fig. S2B).
Substitution of Asp949 by serine in EmbC
CT, the only side chain
in direct contact with the Ca
2+ ion (2.6 A ˚, bidentate, Fig. 3A),
resulted in very poor recombinant expression compared to wild-
type and other point mutants probed in this study (see below).
Together these observations suggest that the Ca
2+ ion is important
for the structural integrity of EmbC
CT.
Structural neighbours
The fold of subdomain II is consistent with the proposed role of
EmbC
CT as an acceptor saccharide recognition module. The
comparison with structural homologues, identified via distance
matrix alignment using the DALI program (http://ekhidna.
biocenter.helsinki.fi/dali_server/, [23]) reinforces this notion.
The vast majority of PDB entries retrieved by DALI (over 300
entries above the default significance threshold of Z=2) match the
b-sandwich fold of subdomain II and represent ‘carbohydrate
binding modules’ (CBM), structural domains that confer carbo-
hydrate-binding specificity, but that lack intrinsic catalytic activity
[21]. CBMs occur frequently as a part of glycoside hydrolase
enzymes and fall into (to date) 61 distinct CBM families (http://
www.cazy.org/). While none of the structural homologues is
particularly close to subdomain II (Z-scores#6.9, root mean
square deviation (RMSD)$3.0 A ˚), the top 10 hits include the
calcium-containing CBM families 6 and 36 (Fig. S3A–C).
Interestingly, in the DALI-generated superposition of EmbC
CT
with Paenibacillus polymyxa endo-1,4-b-xylanase (PDB entry 1UX7,
CBM 36), the Ca
2+ sites match to within 0.9 A ˚, and in the latter,
the Ca
2+ ion makes direct contact with the bound xylobiose ligand
(Fig. S3A). In contrast, only three hits were obtained for
subdomain I of which only the best (PDB entry 2ZAG, Z=3.0,
RMSD 3.4 A ˚ for 66 Ca pairs) showed weak similarity in terms of
secondary structure topology in a limited region of overlap (Fig.
S4). This PDB entry describes the hydrophilic C-terminal domain
of oligosaccharyltransferase STT3 from Pyrococcus furiosus [24], a
membrane-embedded glycosyltransferase of the GT-C superfamily
that catalyses transfer of glycosyl groups from a lipid donor to Asn-
glycosylation sites of the acceptor protein.
Self-assembly in solution
Crystal packing contacts, analysed using the PISA server
(http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html), highlight-
Author Summary
Tuberculosis (TB), an infectious disease caused by the
bacillus Mycobacterium tuberculosis, burdens large swaths
of the world population. Treatment of active TB typically
requires administration of an antibiotic cocktail over
several months that includes the drug ethambutol. This
front line compound inhibits a set of arabinosyltransferase
enzymes, called EmbA, EmbB and EmbC, which are critical
for the synthesis of arabinan, a vital polysaccharide in the
pathogen’s unique cell envelope. How precisely ethambu-
tol inhibits arabinosyltransferase activity is not clear, in part
because structural information of its pharmacological
targets has been elusive. Here, we report the high-
resolution structure of the C-terminal domain of the
ethambutol-target EmbC, a 390-amino acid fragment
responsible for acceptor substrate recognition. Combining
the X-ray crystallographic analysis with structural compar-
isons, site-directed mutagenesis, activity and ligand
binding assays, we identified two regions in the C-terminal
domain of EmbC that are capable of binding acceptor
substrate mimics and are critical for activity of the full-
length enzyme. Our results begin to define structure-
function relationships in a family of structurally unchar-
acterised membrane-embedded glycosyltransferases,
which are an important target for tuberculosis therapy.
Lectin-Like Domain of EmbC
PLoS Pathogens | www.plospathogens.org 2 February 2011 | Volume 7 | Issue 2 | e1001299ed three prominent interaction surfaces burying 390 A ˚ 2, 670 A ˚ 2
and 1100 A ˚ 2 of solvent accessible surface (SAS) per monomer,
respectively (Fig. S5). We probed self-assembly of EmbC
CT by
sedimentation velocity at three different protein concentrations
(Fig. 4A). The distribution C(S) of the sedimentation coefficient S
indicates a dynamic equilibrium between three different molecular
species at 3.1S, 4.6S and 7S, which correspond to apparent
molecular weights of 46.5 kDa, 75.8 kDa and 138.0 kDa,
respectively, compared to the calculated monomer mass of
39.9 kDa. Bearing in mind that under- or overestimates of
apparent masses can occur as a result of fitting a single frictional
coefficient for an ensemble of species with different frictional
ratios, the dominant peak at 4.6S most likely represents a dimer.
The higher molecular weight peak at 7.6S, could be a trimer or
tetramer, but strongly suggests that more than one of the crystal
packing interfaces is able to mediate oligomerisation of EmbC
CT in
vitro.
Carbohydrate binding
Previous studies had attributed to the C-terminal domain of the
Emb proteins a critical role in arabinan chain extension [9,11].
Therefore, we asked whether the isolated domain is able to bind
synthetic acceptor analogues. As the physiological substrate is
chemically complex and diverse, using synthetic acceptor
analogues offered the best chance to obtain an experimental
acceptor-bound complex structure. In previous work, our
Figure 1. Schematic diagram of LAM synthesis and architecture of M. tuberculosis EmbC. A) Schematic representation of the stepwise
assembly of LAM at the membrane of mycobacteria. The precursors of LAM are phosphatidylinositol mannosides (PIM), which contain a
phosphatidyl-myo-inositol core unit. Initially, intracellular a-mannosyltransferases catalyse attachment of mannosyl units to inositol, followed by
flipping of the glycolipid to the extracellular face of the membrane and further chain extension by membrane-embedded mannosyl- and
arabinofuranosyl transferases to generate lipomannan (LM), lipoarabinomannan (LAM) and mannan-capped LAM (ManLAM). Relevant saccharide
donor substrates are as follows: GDP-Man (guanosine-59-diphosphate-a-D-mannose), PPM (C35/C50-polyprenyl-monophospho-mannose), DPA (b-D-
arabinofuranosyl-1-monophosphoryl-decaprenol). ManT and AraT designate mannosyl- and arbinosyltransferases that are as yet uncharacterised. B)
Topology diagram of EmbC based on the hydropathy analysis with TMHMM (www.cbs.dtu.dk/services/TMHMM/). Extracellular loops are labelled E1-
E6 and CT, intracellular loops I1–I7. Functionally important sequence motifs, previously identified in references [10,15], are indicated. The C-terminal
domain (residues 719–1094) is shown as a ribbon diagram.
doi:10.1371/journal.ppat.1001299.g001
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that were modelled on motifs found in mycobacterial AG and
LAM. When incubated with [
14C]-labelled Araf-donor substrate
DPA and isolated mycobacterial membranes in a cell-free Araf
transferase, these molecules acted as potent acceptor mimics [25].
One of these acceptors was the di-arabinoside a-D-Araf-(1R5)-a-
D-Araf-O-(CH2)7CH3 (for short: Ara(1R5)Ara-O-C8, Fig. 4B).
The O-linked octyl tail allowed extraction of the reaction pro-
ducts for qualitative characterisation in vitro. Importantly, the
closely related di-arabinoside a-D-Araf-(1R5)-a-D-Araf-O-CH3
(Ara(1R5)Ara-O-C1) exhibited similar levels of acceptor activity,
demonstrating the O-linked octyl was dispensable for activity [25].
By way of intrinsic tryptophan fluorescence, we probed binding of
Ara(1R5)Ara-O-C8 to EmbC
CT, as well as that of analogous tri-
and penta-arabinofuranosides, [a-D-Araf-(1R5)]2-a-D-Araf-O-
(CH2)7CH3 (Ara-a(1R5)2-Ara-O-C8) and [a-D-Araf-(1R5)]4-a-
D-Araf-O-(CH2)7CH3 (Ara-a(1R5)4-Ara-O-C8, Fig. 4B). Fitting
the binding curves to a single-site saturation model, yielded an
equilibrium dissociation constant Kd of 3.6 mM for the di-
arabinofuranoside Ara(1R5)Ara-O-C8 (Table 2), while the
disaccharide lacking the octyl chain, Ara(1R5)Ara-O-C1, resulted
in a Kd of 11.0 mM. These data confirmed that in the solution
state the octyl chain is not essential for binding, although it may
enhance affinity. Soaking EmbC
CT crystals in cryoprotectant
solution containing 27 mM Ara(1R5)Ara-O-C8 (,3-fold excess
of ligand relative to protein concentration in the crystal)
reproducibly resulted in defined ligand density (Fig. 3B), allowing
us to unequivocally build one Araf unit and the octyl chain of
Ara(1R5)Ara-O-C8, while the second Araf ring remained
invisible, even when contouring the map at near-noise level.
Soaking experiments using the other acceptor analogues, for which
solution binding was examined, failed to reveal electron density for
the ligand. The soaked di-arabinofuranoside ligand is positioned
between two symmetry-related copies of EmbC
CT, forming non-
covalent contacts only with residues in subdomain I, but not with
the CBM-like subdomain II, in contrast to our expectation. The
Araf moiety packs against helix H6 and the H6-S13 loop (Fig. 2),
forming three direct H-bond contacts with protein: O2 binds to
Table 1. Crystallographic data.
Data collection
Data set Native SeMet-IP SeMet-Peak SeMet-Remote
Wavelength (A ˚) 0.9763 0.9799 0.9797 0.9763
Space group P6522 P6522 P6522 P6522
Unit cell: a, c (A ˚) 129.1, 136.7 130.3, 137.7 130.3, 137.7 130.3, 137.7
Resolution
(1) 46.922.0 (2.1122.0) 29.522.7 (2.8522.7) 29.522.7 (2.8522.7) 29.522.7 (2.8522.7)
Completeness
(1) 100 (100) 99.9 (100) 99.9 (100) 99.5 (97.9)
Rsym (%)
(1) 7.3 (56.4) 11.1 (41.8) 11.2 (42.4) 5.8 (12.9)
I/s(I)
(1) 27 (5.3) 20.9 (7.1) 20.4 (6.9) 32.4 (19.1)
Redundancy
(1) 14.4 (14.5) 17.6 (18.0) 17.6 (18.1) 17.5 (17.7)
Refinement
Resolution 43.322.0
Unique Reflections 86,163
Protein residues 285
Ara(1R5)Ara-O-C8 1
Ca
2+ 1
PO4
32 1
Water molecules 113
Rwork, Rfree
(2) (%) 18.7, 20.7
Wilson B-factor (A ˚2)2 7 . 9
Aver. B-factor (all, A ˚2)3 2 . 3
Protein (A ˚2)3 2 . 2
Ara(1R5)Ara-O-C8 (A ˚2)4 6 . 1
Solvent (A ˚2)3 4 . 7
RMSD B-factors (A ˚2) 2.3, 2.5
RMSD bonds (A ˚) 0.006
RMSD angles (u) 1.02
Ramachandran plot
(3)
Favoured (%) 97.8
Outliers 1 of 278
(1) High resolution shells are given in parentheses.
(2) 5% of reflections were set aside for the test set.
(3) Ramachandran statistics was calculated using MolProbity (molprobity.biochem.duke.edu; [47]).
doi:10.1371/journal.ppat.1001299.t001
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and O3 to Nd2 of Asn7409 (primed residues indicating the
symmetry mate). In contrast, the octyl chain binds between helix
H0 and the S13–S14 loop of the symmetry mate (Fig. 3B). Ligand
binding promotes ordering of the N-terminus of helix H0, where 3
additional residues become visible compared to apo, and induces a
conformational shift of aspartate residues 1051 and 1052 in the
S13–S14 loop (Fig. S6). While this crystallographic complex
structure did not reveal binding to the CBM-like subdomain II, it
is possible that crystal lattice formation of EmbC
CT interferes with
binding at a site on subdomain II. We, therefore, asked whether
the structural superimposition with saccharide-bound CBM
domains could be exploited to predict potential additional binding
sites. We note that ligand binding modes and substrate specificity
of CBM domains can differ even within the same CBM family
[21,26]. Thus, structural alignments of the protein scaffolds are
unlikely to accurately predict the precise modes of binding and
potential specificity-determining interactions. Nevertheless, super-
imposing carbohydrate-bound structures of CBM domains with
the 10-highest DALI Z-scores (with respect to the non-redundant
PDB90 subset) shows two clusters of putative ligand binding sites
in subdomain II (Fig. 3C): (1) near the Ca
2+ site and the S3–S4
loop, and (2) on the open surface of the ‘outer’ b-sheet (strands S2,
S4, S10, S6, S7). Virtually all ligands in the first cluster sterically
clash with the loops that coordinate the Ca
2+ site. Without
invoking a conformational change that exposes the Ca
2+ to
solvent, this site appears unable to accommodate a ligand. In
contrast, in the second cluster, only minor steric hindrance occurs
between EmbC
CT and the superimposed ligands, and thus this site
appeared more plausible as a carbohydrate-binding site.
Mutagenesis and activity in full-length EmbC
The crystallographic complex of EmbC
CT bound to Ara(1-
R5)Ara-O-C8 and the structural superposition with carbohy-
drate-bound homologues had indicated two distinct regions in
EmbC
CT as potential sites for carbohydrate binding (Fig. S7A). In
order to probe the relevance of these two sites, we asked whether
replacement of endogenous EmbC with recombinant EmbC
carrying appropriate point mutations would alter the cell wall
composition of M. smegmatis. Aromatic residues frequently mediate
binding of carbohydrate ligands to CBMs [21]. Given the H-bond
contacts between Trp985 and Ara(1R5)Ara-O-C8 in subdomain
I, and the central position of Trp868 of the ‘outer’ (solvent-
exposed) b-sheet of subdomain II (Fig. 3C and Fig. S7A), we
probed these two residues in the first instance.
Using a phage-mediated transduction method for allelic
exchange [27], we generated an EmbC-deficient strain of M.
smegmatis (M. smegmatis DembC), which was complemented with
plasmids encoding either wild-type (full length) M. tuberculosis
EmbC or mutant forms thereof. In accordance with previously
reported data [9], our M. smegmatis DembC strain retains
lipomannan (LM) synthesis, but is deficient in LAM (Fig. 4C –
lane 2). The abrogation of LAM biosynthesis can be directly
attributed to the loss of EmbC, which is involved in the early
synthesis of a(1R5)-Araf arabinan elongation of LM, the
immediate LAM precursor (Fig. 1A) [9]. We utilised this
phenotype by analysing LM/LAM resulting from complementa-
tion of M. smegmatis DembC with plasmid pVV16-Mt-embC,
encoding full-length M. tuberculosis EmbC, and plasmids pVV16-
Mt-embC
W868A or pVV16-Mt-embC
W985A, which encode point
mutants W868A and W985A of full-length M. tuberculosis EmbC,
respectively. Complementation with wild type EmbC largely
restored the normal phenotype (Fig. 4C – lane 3), whereas
complementation with the point mutants failed to re-establish
LAM synthesis (Fig. 4C – lanes 4, 5). We verified by Western blot
that loss of LAM synthesis was not due to failure of the plasmid-
encoded protein to incorporate into the membrane of M. smegmatis
DembC (Supporting Fig. S7B). These results suggest that the
structural perturbations caused by the individual single-site
mutations are sufficient to disrupt the function of EmbC.
Differential acceptor binding of EmbC
CT mutants
In order to establish whether loss of activity was linked to
compromised acceptor binding, we introduced the single-residue
mutations W868A or W985A into expression plasmids encoding
EmbC
CT. In addition, we prepared analogous expression plasmid
Figure 2. Stereo diagram of EmbC
CT and topology of its subdomains. A) Stereo ribbon diagram of EmbC
CT with definition of the secondary
structure elements. Grey spheres indicate the boundaries of the disordered loops. The Ca
2+ ion (yellow sphere), and positions of Trp985 (yellow sticks)
and of the Ara(1R5)Ara-O-C8 ligand (magenta) are shown. B) Topology diagrams of subdomains I (top) and II (bottom), illustrating the connectivity
of secondary structure elements and the jelly roll topology of subdomain II.
doi:10.1371/journal.ppat.1001299.g002
Lectin-Like Domain of EmbC
PLoS Pathogens | www.plospathogens.org 5 February 2011 | Volume 7 | Issue 2 | e1001299constructs bearing mutations on Asn740 (to Ala, binding site
subdomain I), Gln899 (to Ser) and His911 (to Ala, binding site
subdomainII) and Asp949 (to Ser,Ca
2+bindingsite,seeSupporting
Fig. S7A). Two constructs (Q899S, D949S) did not express well
enough to yield protein suitable for in vitro assays. For those proteins
that were produced successfully, proper folding was verified by far-
UV circular dichroism spectroscopy (Supporting Fig. S7C). When
comparing binding of the di- and penta-arabinoside acceptor
analogues (Fig. 4B and Fig. 5) that both carry the O-linked octyl tail,
it was striking that the substitutions W868A and W985A affected
binding of these ligands in a differential fashion. While the W985A
mutation virtually abrogated binding of the disaccharide Ara(1-
R5)Ara-O-C8, the W868A substitution preserved binding of this
particular ligand, with only a modestly higher Kd (Table 2, Fig. 5A).
In contrast, binding of the penta-arabinoside Ara(1R5)4Ara-O-C8
was insensitive to the W985A mutation, but completely inhibited in
responseto the W868Amutation.Likewise,mutatingAsn740toAla
weakened binding of the disaccharide (Table 2), consistent with its
positionwithinH-bond distanceofthe ordered ArafinsubdomainI,
whereas the distant H911A mutation in subdomain II had no effect
on this ligand. Thus, the differential effect of mutations in the
putative binding sites in subdomain I and II on binding of acceptor
analogues that differ only in length, strongly suggests that these bind
preferentially to distinct sites on EmbC
CT.
Discussion
Polyprenyl-dependent glycosyltransferases of superfamily GT-C
are still awaiting the determination of a structure of an intact, full-
length enzyme, but structures of individual hydrophilic domains
have begun to emerge [24] (see also PDB entry 3BYW). As a first
step towards the complete structural characterisation of the Emb
Araf-transferases in M. tuberculosis, we have determined the crystal
structure of the hydrophilic C-terminal domain of EmbC, the
enzyme responsible for arabinan chain elongation in LAM
synthesis and a target for the front line antibiotic EMB [5]. We
found that the architecture of this domain comprises two
subdomains, one of which folds as a lectin- or CBM-like domain,
the other one shows weak similarity to the C-terminal hydrophilic
domain of an unrelated GT-C glycosyltransferase, oligosaccharyl
transferase STT3 [24]. The match between subdomain I and the
so-called CC region of STT3 is poor (Fig. S4), and is limited to
core secondary structure elements. Nevertheless, the DALI-
derived superposition aligns the second Trp in STT3’s highly
conserved WWDYG motif with EmbC’s Trp985, a side chain we
showed is critical for enzymatic activity. Thus the alignment lends
additional support to the notion of Trp985 sitting at a critical
junction of the C-terminal domain of EmbC.
Sequence comparison of the Emb C-terminal domains (Fig. S1)
strongly suggests that the disulfide bond Cys749-Cys993 is a
conserved structural feature. Forming a topologically intuitive
demarcation of this domain, this covalent link presumably
enhances the stability of the C-terminal domain at physiological
conditions in the host. The disordered loops (residues 794–825,
1016–1037) encompass regions of high sequence diversity as
Figure 3. Metal binding and putative carbohydrate binding
sites. A) Ca
2+ site (green sphere) superimposed with an anomalous
difference density map (3s contour level) calculated with in-house
diffraction data (CuKa radiation). Metal-ligand interactions are indicated
with distances in units of A ˚.B )sA-weighted Fo2Fc difference density
map (3s contour level) of the Ara(1R5)Ara-O-C8 binding site calculated
with phases and calculated amplitudes Fc of the model coordinates
prior to incorporation of the ligand. Two symmetry-related molecules
are shown (yellow and pink sticks, respectively). Primed residue
numbers refer to the symmetry mate. C) Identification of putative
carbohydrate binding sites in subdomain II by superimposing EmbC
CT
with carbohydrate–bound structural homologues. Ligands (shown as
stick models) were drawn according to the DALI-alignment with the Ca-
traces of structural neighbours. Ligand structures shown in this diagram
encompass PDB entries 1ux7, 1w9t, 1o8s, 1w9w, 1uy2, 1od3, 2vzq,
2w47, 2w87, 2cdp, 2cdo, 1uyy, 1uy0, representing the top 10 matches
of the DALI search against the PDB90 subset (chains that are less than
90% identical in sequence to each other; Z-scores 6.9–6.3, RMSD 3.0–
3.6 A ˚).
doi:10.1371/journal.ppat.1001299.g003
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structure. Given the latter, one could speculate that these
disordered regions are linked to acceptor discrimination, and/or
that ordering might be induced by contacts with adjacent
structural elements in the context of the full-length enzyme.
It has previously been proposed that the Emb enzymes may
function as dimers, possibly in the combination EmbA/EmbB and
EmbC/EmbC [11,28]. Our sedimentation velocity data now
provide supporting evidence for self-assembly of EmbC, although
we cannot rule out that the observed oligomerisation occurs solely
as a result of separating EmbC
CT from the rest of the protein.
However, the presence of dimers and trimers (or tetramers)
(Fig. 4A) in solution demonstrated that at least two of the observed
crystal packing interfaces were able to mediate self-assembly of
EmbC
CT. While thile the most-extended packing interface (SAS
buried 1100 A ˚ 2) is mediated by structural elements (helices H0
and H6) that are close the truncation site, the second-largest
interface (SAS buried 670 A ˚ 2) is mediated by strand S2, and
distant to the truncation site. Indeed, the latter self-assembly
interface generates a continuous b-sheet that extends across the
monomer-monomer boundary (Fig. S5C), hinting that it could be
preserved in the full-length enzyme.
The presence of a CBM-like subdomain in EmbC
CT is
consistent the proposed role of the C-terminal domain in acceptor
substrate recognition [10,11]. Among these structurally diverse
carbohydrate binding modules, the b-sandwich fold seen in
Figure 4. Self-assembly, ligand binding and cell wall analysis. A) Self-assembly of EmbC
CT by analytical ultracentrifugation in sedimentation
velocity mode. Protein concentration for the individual distributions is given in units of mg ml
21. Peaks at 3.1S, 4.6S and 7S correspond to fitted
molecular weights of 46500 Da, 75800 Da and 138000 Da, respectively. B) Saturation binding of arabinofuranosyl acceptor analogues to EmbC
CT
probed by intrinsic tryptophan fluorescence. The chemical structures of the ligands are indicated. Data points were fitted to a single site-binding
model. C) Effect of substitutions W868A and W985A in full-length M. tuberculosis EmbC on in vivo lipomannan (LM) and LAM synthesis analysed by
SDS-PAGE. Lanes are as follows: (1) M. smegmatis wild-type; (2) M. smegmatis DembC; (3) M. smegmatis DembC+pVV16-Mt-embC; (4) M. smegmatis
DembC+pVV16-Mt-embC
W868A; (5) M. smegmatis DembC+pVV16-Mt-embC
W985A.
doi:10.1371/journal.ppat.1001299.g004
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CT is most common [21]. The differential response of the
ligands of different length to the Trp mutations in subdomains I
and II provides compelling evidence for the presence of two
separate ligand binding sites in EmbC
CT. This response also links
the loss of Araf transferase activity in the Trp mutants to
compromised acceptor binding. Although we were not successful
in crystallising a complex structure that directly demonstrates
binding of an acceptor analogue to the CBM-like subdomain II,
the dramatic loss of binding affinity of the penta-arabinoside
acceptor for the mutant EmbC
CT(W868A) (Fig. 5B, Table 2) and the
corresponding loss of LAM synthesis, are strong indications that
subdomain II indeed functions as a carbohydrate binding module.
We note that the W868A mutation has also a modest effect on
binding of Ara(1R5)Ara-O-C8 (,2.5-fold increase in Kd, Table 2),
despite the obvious preference of this ligand for binding to
subdomain I, as shown by the structure and the response to the
W985A mutation. This observation could indicate that Ara(1-
R5)Ara-O-C8 also associate with the CBM-like subdomain II,
albeit with considerably lower affinity. The converse may be true
for the penta-saccharide as well, although the affinities we
measured show no corresponding signature. Comparison of the
affinities for binding of the tri- and pentasaccharide to wild type
EmbC
CT clearly indicates that binding to subdomain II is tighter
for longer polysaccharides, as these can be expected to make
additional contacts. However, the apparent switch in binding
preference from the site in subdomain I to that in subdomain II on
going from two to five Araf units is less straightforward to explain.
If, as the structure suggests, only the octyl tail and the first Araf
unit were the major determinants of binding to subdomain I, one
would expect to see evidence for binding of Ara(1R5)4Ara-O-C8
to subdomain I, that is, a significant change in affinity when
mutating Trp985. Thus, while the octyl tail clearly influences
binding of the di-saccharide, this appears to be less the case for the
tri- and penta-saccharides. This observation is in line with the
dispensable nature of the octyl chain when the above ligands are
used as acceptor mimics in cell-free Araf transferase assays [25].
Overall, a string of genetic and biochemical evidence consis-
tently indicated that enzymatic activity of the Emb Araf-
transferases is associated with loops displayed on the extra-cellular
face of the membrane. For instance, the most frequent point
mutation present in EMB-resistant clinical isolates of M. tuberculosis
concerns residue Met306 in EmbB (=Met300 in EmbC, see Fig. 1)
[20], only a few residues downstream of the GT-C-specific, strictly
conserved DDX motif in the E2 loop [15]. Berg et al. showed that
loop E6 carries a functionally relevant, conserved proline-
containing sequence motif [10], consistent with findings in the
Emb protein of C. glutamicum [14]. Moreover, a crystal structure of
the first extracellular loop of the Emb Araf-transferase of the
related organism Corynebacterium diphtheriae has become available
very recently (PDB entry 3BYW; Tan K., Hatzos C., Abdullah J.,
Joachimiak A., unpublished). The domain of the E1 loop displays
a b-sandwich fold with similarity to the fold of galectin [29], but is
not superimposable on that of subdomain II of EmbC
CT. The
galectin-like fold again hints to a potential function in carbohy-
drate binding – perhaps the sugar moiety of the Araf-donor DPA.
In conclusion, the present structure of the C-terminal domain of
M. tuberculosis EmbC provides a first corner stone towards
assembling the structure of the full-length enzyme, and allows
us to begin probing this essential enzyme in a rational and
targeted fashion.
Table 2. Ligand binding parameters.
Protein Ligand Fmax Kd (mM)
Standard
Error*
EmbC
CT Ara(1R5)Ara-O-C8 0.22 3.65 61.72
Ara(1R5)Ara-O-C1 0.26 11.03 64.01
Ara(1R5)2Ara-O-C8 0.105 25.30 64.98
Ara(1R5)4Ara-O-C8 0.157 18.02 66.97
Galb(1R5)Gal-O-C8 a
EmbC
CT(N740A) Ara(1R5)Ara-O-C8 0.141 26.46 66.91
EmbC
CT(W868A) Ara(1R5)Ara-O-C8 0.162 9.91 61.87
Ara(1R5)4Ara-O-C8 a
EmbC
CT(H911A) Ara(1R5)Ara-O-C8 0.170 3.99 60.43
EmbC
CT(W985A) Ara(1R5)Ara-O-C8 a
Ara(1R5)4Ara-O-C8 0.164 12.17 66.25
*Derived from non-linear fitting of data recorded to DFemission=Fmax6[L]/(Kd+[L])
(single site saturation binding curve).
a, no change in Femission over background in response to ligand additions.
doi:10.1371/journal.ppat.1001299.t002
Figure 5. Differential binding of di- and penta-arabinofurano-
side acceptor analogues to point mutants of EmbC
CT. Ligand
binding was analysed by intrinsic tryptophan fluorescence, comparing
saturation binding of wild type EmbC
CT,E m b C
CT(W868A) and
EmbC
CT(W985A) for the ligands Ara(1R5)Ara-O-C8 (panel A) and
Ara(1R5)4Ara-O-C8 (panel B). Equilibrium dissociation constants
derived from non-linear fitting are reported in Table 2.
doi:10.1371/journal.ppat.1001299.g005
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Reagents
Plasmids were propagated during cloning in E. coli Top10 cells
(Invitrogen). All restriction enzymes, T4 DNA ligase and Phusion
DNA polymerase enzymes were sourced from New England
Biolabs. Oligonucleotides were from MWG Biotech Ltd and PCR
fragments were purified using the QIAquick gel extraction kit
(Qiagen). Plasmid DNA was purified using the QIAprep
purification kit (Qiagen).
Recombinant protein
A 1125-bp region coding for the C-terminal domain (residues
719–1094) of EmbC was cloned from genomic DNA of M.
tuberculosis H37Rv using PCR primers (restriction sites under-
lined) GATCGATCCATATGGAGGTGGTATCGCTGACC-
CAG (forward) and GATCGATCCTCGAGCTAGCCTCTG-
CGCAACGGC (reverse). The PCR product was ligated into
plasmid pET23b (NdeI, XhoI restriction sites), yielding the His6-
tagged pET23b-EmbC
CT construct, whose sequence was verified
(School of Biosciences Genomics Facility, University of Birming-
ham). For expression, E. coli C41(DE3) cells were transformed with
pET23b-EmbC
CT using the rubidium chloride method. Over-
night cultures (5 ml LB medium, 100 mg/ml ampicillin) were used
to inoculate bulk cultures (461 litre LB, 100 mg/ml ampicillin,
37uC, 200 rpm). Seleno-methionine derivatised EmbC
CT was
produced using the same expression plasmid and host, but
following the feedback inhibition protocol described in [30].
Cultures were induced at OD600=0.5 using 1 mM IPTG (12 h,
16uC). Cells were harvested (60006g, 15 min), washed with 20 ml
phosphate buffered saline, and frozen. Pellets were re-suspended in
50 mM KH2PO4 (pH 7.9), 300 mM NaCl, 1 mM PMSF, 15 mg/
ml benzamidine, DNAse and RNAse (50 mg/ml), and sonicated
(30 sec ON/OFF cycles, total of 8 cycles). The lysate was cleared
(30 min, 280006g,4 uC) and passed over a HiTRAP Ni
2+-NTA
column (GE Healthcare), equilibrated in 50 mM KH2PO4
(pH 7.9), 300 mM NaCl, and eluted using a step-gradient of
50–500 mM imidazole. The purification was monitored by 12%
SDS-PAGE. Fractions containing EmbC
CT (250, 500 mM
imidazole) were pooled and dialysed against 50 mM KH2PO4
(pH 7.9), 300 mM NaCl, and concentrated by ultrafiltration to
,15 mg/ml.
Structure determination
Hanging drop vapour diffusion was used to grow crystals of
EmbC
CT over a reservoir of 0.1 M sodium acetate pH 4.4,
80 mM ammonium phosphate, mixing 1 ml of protein with 1 mlo f
reservoir solution. Crystals were cryoprotected in reservoir
solution, adding up to 12% ethylene glycol and 12% glycerol,
and flash frozen in liquid nitrogen. Native and 3-wavelength
SeMet MAD data were recorded on beamline ID23-1 (ESRF,
Grenoble, France). Diffraction images were processed using XDS
and XSCALE [31] (Table 1). Selenium sites and phases were
obtained using standard procedures (SHELXD [32], SHARP v2.2
[33] SOLOMON [34]) leading to a readily interpretable electron
density map (Fig. S2A). The ARP/wARP-built [35] initial model
was rebuilt in COOT [36], with intermittent refinement against
native data (REFMAC5 [37], PHENIX.REFINE [38]). Temper-
ature factor modelling included TLS refinement [39]. The final
model has good stereochemistry and comprises EmbC residues
735–794, 825–1015 and 1038–1067, 113 water molecules, one
molecule of Ara(1R5)Ara-O-C8, one Ca
2+ and one phosphate ion
(Table 1).
Solution binding assay by intrinsic tryptophan
fluorescence
Intrinsic tryptophan fluorescence (ITF) experiments were
carried out using a PTI QuantaMaster 40 spectrofluorimeter,
recording data with the FeliX32 software package (PTI, Birming-
ham, New Jersey, USA). The excitation wavelength was set to
294 nm and the fluorescence emission (Femission) was recorded
between 300–400 nm for each ligand aliquot added to a 200 ml
solution containing 20 mM EmbC
CT in 50 mM KH2PO4
(pH 7.9), 300 mM NaCl. For EmbC
CT, the emission maximum
(Femission
max) was at l=338 nm, providing a basal Femission coordinate
for the collection of subsequent ITF data. The change in
fluorescence emission (DFemission) was calculated by subtracting
Femission (recorded 2 min after each ligand addition) from Femission
max,
and the data was then plotted against ligand concentration, [L] (3
independent experiments). A plot of DFemission at l=338 nm vs. [L]
was fitted to the saturation binding equation using GraphPad
Prism software:
DFemission~Fmax| L ½  = Kdz L ½  ðÞ :
Circular dichroism spectroscopy
Far-UV circular dichroism (CD) spectra were recorded at 25uC
using a Jasco J-715 spectropolarimeter and a cell of 0.01 cm path
length. Proteins EmbC
CT, EmbC
CT(N740A), EmbC
CT(W868A),
EmbC
CT(H911A) and EmbC
CT(W985A) were dialysed into 50 mM
KH2PO4 (pH 7.9), 50 mM NaF to a final concentration of
0.5 mg/ml each. Spectra were recorded of 250 ml aliquots of each
protein by measuring ellipticity from 195–260 nm, using a
bandwidth of 2 nm and a scan speed of 100 nm/min. Spectra
were normalised by subtracting the spectrum of buffer alone
(baseline).
Analytical ultracentrifugation
Sedimentation velocity experiments were performed using a
Beckman Proteome XL-I analytical ultracentrifuge equipped with
absorbance optics. EmbC
CT was dialysed into 50 mM KH2PO4
(pH 7.9), 300 mM NaCl, and loaded into cells with two channel
Epon centre pieces and quartz windows. A total of 100 absorbance
scans (280 nm) were recorded (40,000 rpm, 4uC) for each sample,
representing the full extent of sedimentation of the sample. Data
analysis was performed using the SEDFIT software, fitting a single
friction coefficient [40].
Generation of embC-deficient M. smegmatis and
complementation plasmids
Approximately 1 kb of upstream and downstream flanking
sequences of the embC gene (MSMEG2785) were PCR amplified
from M. smegmatis mc
2155 genomic DNA using the primer pairs
MSEMBCLL, MSEMBCLR, MSEMBCRL and MSEMBCRR,
respectively (sequences listed in Supporting Information Table S1).
Following restriction digestion of the primer incorporated AlwNI
sites, the PCR fragments were cloned into AlwNI-digested p0004S
to yield the knockout plasmid pDMSMEGEMBC which was then
packaged into the temperature sensitive mycobacteriophage
phAE159 as described previously [27] to yield phasmid DNA of
the knockout phage phDMSMEGEMBC. Generation of high titre
phage particles and specialized transduction were performed as
described earlier [27,41]. Deletion of MSMEGEMBC in one
hygromycin-resistant transductant was confirmed by Southern
blot. For complementation, M. tuberculosis embC was cloned using
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listed in Supporting Information Table S1) and blunt-end ligated
into SmaI digested pUC18. For QuikChange mutagenesis
(Stratagene) of pUC18-Mt-embC W868A and W985A codons,
primer pairs W868A-sense/-antisense and W985A-sense/-anti-
sense (sequences in Supporting Information Table S1, each with
59-phosphate modifications) were used. The 3301 bp product was
extracted from plasmids (pUC18-Mt-embC, pUC18-Mt-embC
W868A
and pUC18-Mt-embC
W985A) digested with NdeI and HindIII, and
sub-cloned into the similarly digested mycobacterial shuttle vector
pVV16 to yield pVV16-Mt-embC, pVV16-Mt-embC
W868A and
pVV16-Mt-embC
W985A. These plasmids were then used to
transform M. smegmatisDembC to yield clones resistant to both
hygromycin and kanamycin.
Point mutations in recombinant EmbC
CT
QuikChange mutagenesis (Stratagene) was carried out using
pET23b-Mt-embC
CT (generated as described above). Primer pairs
used for the codon alterations N740A, W868A, Q899S, H911A
and W985A are listed in the Supporting Information Table S1.
Mutant plasmids were subsequently transformed individually into
E. coli C41 (DE3). Mutant proteins were expressed and purified as
described above.
Analysis of lipoglycans
Lipoglycans form M. smegmatis strains were extracted as
described previously [42]. Dried cells were resuspended in de-
ionized water and disrupted by sonication (MSE Soniprep 150,
12 mm amplitude, 60 s on, 90 s off for 10 cycles, at 4uC). An
equal volume of ethanol was added to the cell suspension and the
mixture was refluxed at 68uC, for 12 h intervals, followed by
centrifugation and recovery of the supernatant. The C2H5OH/
H2O extraction process was repeated five times and the
combined supernatants dried. The dried supernatant was then
subjected to hot-phenol treatment by addition of phenol/H2O
(80%, w/w) at 70uC for 1 h, followed by centrifugation and the
aqueous phase was dialyzed using a 1500 MWCO membrane
(Spectrapore) against de-ionized water. The retentate was dried,
resuspended in water and sequentially digested with a-amylase,
DNase, RNase, chymotrypsin and trypsin. The retentate was
further dialyzed using a 1500 MWCO membrane (Spectrapore)
against deionized water. The eluates were collected, extensively
dialysed against deionized water, concentrated and analyzed by
15% SDS-PAGE using a Pro-Q emerald glycoprotein stain
(Invitrogen).
Accession numbers
The accession number for the coordinates and structure factors
of the C-terminal domain of EmbC in the Protein Data Bank
(http://www.rcsb.org) is 3PTY.
Supporting Information
Figure S1 Sequence alignment of EmbC
CT. CLUSTALW2-
aligned sequences of the C-terminal domain of EmbC (residues
719–1094) and related Emb enzymes. Species names are
abbreviated as Mt=M. tuberculosis,M s = M. smegmatis,C g = C.
glutamicum. The sequence alignment was formatted using ESPript
(espript.ibcp.fr, reference [43]). Dashed underlines indicate
disordered region, orange and blue bars indicate subdomains I
and II, respectively, and residue numbers refer to the sequence of
M. tuberculosis EmbC.
Found at: doi:10.1371/journal.ppat.1001299.s001 (1.94 MB TIF)
Figure S2 Experimental electron density and Ca
2+ site. A)
Solvent-flattened electron density map, contoured at 1.2 s,
calculated based on the seleno-methionine substructure, and
superimposed over the final refined model of EmbC
CT (yellow
sticks). The region shown is the S10–S11 loop with the Ca
2+
binding site. B) Comparison of sA-weighted Fo2Fc density
(contour level 4.5s) without EDTA (green), and with 10 mM
EDTA (purple) in the cryo-buffer. Density was calculated with
phases and calculated amplitudes of a protein-only coordinate set.
The height for the Ca
2+ peak is 21s (no EDTA) and 7s (10 mM
EDTA), respectively, while the height of the nearby phosphate
peak is ,7.5s in both maps.
Found at: doi:10.1371/journal.ppat.1001299.s002 (3.06 MB TIF)
Figure S3 Comparison of subdomain II of EmbC
CT with
structural neighbours. EmbC
CT (blue strands, green helices)
superimposed over structural neighbours (yellow ribbons) identi-
fied by DALI, reference [23]. A) Carbohydrate binding module
(CBM) of Paenibacillus polymyxa endo-1,4-b-xylanase (CBM family
36) in complex with b-D-xylopyranose trisaccharide (yellow sticks,
1UX7, reference [44]). B) CBM family 6: Cellvibrio mixtus cellulase
B bound to a b-D-glucose trisaccharide (red sticks, 1UYY,
reference [26]) C) CBM family 6: Bacillus halodurans BH0236
bound to xylobiose (red sticks, 1W9T, reference [45]). Bound Ca
2+
ions are shown as spheres in green and magenta for EmbC
CT and
the superimposed CBM, respectively. The side chain of Trp868 in
the ‘outer’ b-sheet of EmbC
CT is shown in grey sticks.
Found at: doi:10.1371/journal.ppat.1001299.s003 (1.97 MB TIF)
Figure S4 Superposition of EmbC
CT with Pyrococcus furiosus
STT3’s C-terminal domain. Superposition of EmbC
CT with the
‘central core’ domain of the C-terminal hydrophilic domain of
oligosaccharyltransferase Pyrococcus furiosus STT3 (yellow ribbon,
reference [24]) calculated using DALI. Secondary structure
elements of EmbC
CT with matches in STT3 are labelled in
accordance to Figs. 2 and S1. Side chains of the catalytic
WWDYG motif in STT3 and of the corresponding tryptophan
residue in EmbC
CT (Trp985) are shown in blue and red sticks,
respectively. The view in panel B is rotated by 90u about the
vertical axis relative to panel A, and restricted to subdomain I
(residues 735–759, 968–1067).
Found at: doi:10.1371/journal.ppat.1001299.s004 (1.19 MB TIF)
Figure S5 Major packing interfaces of the EmbC
CT crystal
lattice. A) Arrangement of 3 copies of EmbC
CT on the crystal
lattice around the two major packing interfaces, burying 1100 A ˚ 2
(green-magenta) and 670 A ˚ 2 (green-gray) of solvent-accessible
surface (SAS) per monomer. B) The helix H0-mediated packing
interface burying1100 A ˚ 2 SAS per monomer. C) The strand S2-
mediated packing interface (670 A ˚ 2 SAS buried per monomer)
demonstrating b-sheet formation across the interface.
Found at: doi:10.1371/journal.ppat.1001299.s005 (1.82 MB TIF)
Figure S6 Conformational changes in the ligand binding site
between apo and Ara(1R5)Ara-O-C8-bound structures of
EmbC
CT. Blue and red density corresponds to contour levels of
+3s and 23s, respectively, of a sA-weighted Fo2Fc difference
map calculated with phases and amplitudes Fc of the apo model
(cyan sticks) and observed amplitudes Fo of the Ara(1R5)Ara-O-
C8-bound structure (yellow sticks).
Found at: doi:10.1371/journal.ppat.1001299.s006 (1.06 MB TIF)
Figure S7 Mutations in EmbC, membrane incorporation of
recombinant EmbC and CD analysis of EmbC
CT point mutants.
A) Ribbon diagram of EmbC
CT, with subdomains I and II shown
with orange and blue b-strands, respectively. The Ara(1R5)Ara-
O-C8 ligand (and one of its symmetry-related copies) are shown in
Lectin-Like Domain of EmbC
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from the structural superposition of EmbC
CT with the family 6
CBM of b-agarase (PDB entry 2CDO, reference [46]). Mutated
residues are indicated with their sequence numbers. B) Plasmids
pVV16 encoding full-length EmbC, or point mutants thereof,
were transformed into an embC-deficient M. smegmatis. Cell
homogenates were separated into membrane (M) and cytosolic
(C) fractions, and probed with an anti-His6 antibody (Roche). The
lanes are as follows: 1 - pVV16 (empty vector), 2 - pVV16-Mt-
embC, 3 - pVV16-Mt-embC
W868A, 4 - pVV16-Mt-embC
W985A.C )
Far-UV circular dichroism spectra of recombinant EmbC
CT (wild-
type and point mutants).
Found at: doi:10.1371/journal.ppat.1001299.s007 (1.28 MB TIF)
Table S1 Primer sequences used for mutagenesis.
Found at: doi:10.1371/journal.ppat.1001299.s008 (0.06 MB
DOC)
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